293 related articles for article (PubMed ID: 37294406)
1. Recent advancement of HDAC inhibitors against breast cancer.
Mehmood SA; Sahu KK; Sengupta S; Partap S; Karpoormath R; Kumar B; Kumar D
Med Oncol; 2023 Jun; 40(7):201. PubMed ID: 37294406
[TBL] [Abstract][Full Text] [Related]
2. Rational Design and Development of HDAC Inhibitors for Breast Cancer Treatment.
Mody D; Bouckaert J; Savvides SN; Gupta V
Curr Pharm Des; 2021; 27(45):4610-4629. PubMed ID: 34533439
[TBL] [Abstract][Full Text] [Related]
3. HDAC Inhibitors for the Therapy of Triple Negative Breast Cancer.
Maccallini C; Ammazzalorso A; De Filippis B; Fantacuzzi M; Giampietro L; Amoroso R
Pharmaceuticals (Basel); 2022 May; 15(6):. PubMed ID: 35745586
[TBL] [Abstract][Full Text] [Related]
4. Discovery of a Novel G-Quadruplex and Histone Deacetylase (HDAC) Dual-Targeting Agent for the Treatment of Triple-Negative Breast Cancer.
Jiang XC; Tu FH; Wei LY; Wang BZ; Yuan H; Yuan JM; Rao Y; Huang SL; Li QJ; Ou TM; Wang HG; Tan JH; Chen SB; Huang ZS
J Med Chem; 2022 Sep; 65(18):12346-12366. PubMed ID: 36053318
[TBL] [Abstract][Full Text] [Related]
5. Structure-Based Design of a Selective Class I Histone Deacetylase (HDAC) Near-Infrared (NIR) Probe for Epigenetic Regulation Detection in Triple-Negative Breast Cancer (TNBC).
Zhang K; Liu Z; Yao Y; Qiu Y; Li F; Chen D; Hamilton DJ; Li Z; Jiang S
J Med Chem; 2021 Apr; 64(7):4020-4033. PubMed ID: 33745280
[TBL] [Abstract][Full Text] [Related]
6. Identification of potent HDAC 2 inhibitors using E-pharmacophore modelling, structure-based virtual screening and molecular dynamic simulation.
Pai P; Kumar A; Shetty MG; Kini SG; Krishna MB; Satyamoorthy K; Babitha KS
J Mol Model; 2022 Apr; 28(5):119. PubMed ID: 35419753
[TBL] [Abstract][Full Text] [Related]
7. Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells.
Marijon H; Lee DH; Ding L; Sun H; Gery S; de Gramont A; Koeffler HP
Biomed Pharmacother; 2018 Mar; 99():543-551. PubMed ID: 29902865
[TBL] [Abstract][Full Text] [Related]
8. Histone Deacetylases as New Therapeutic Targets in Triple-negative Breast Cancer: Progress and Promises.
Garmpis N; Damaskos C; Garmpi A; Kalampokas E; Kalampokas T; Spartalis E; Daskalopoulou A; Valsami S; Kontos M; Nonni A; Kontzoglou K; Perrea D; Nikiteas N; Dimitroulis D
Cancer Genomics Proteomics; 2017; 14(5):299-313. PubMed ID: 28870998
[TBL] [Abstract][Full Text] [Related]
9. Small molecule HDAC inhibitors: Promising agents for breast cancer treatment.
Huang M; Zhang J; Yan C; Li X; Zhang J; Ling R
Bioorg Chem; 2019 Oct; 91():103184. PubMed ID: 31408831
[TBL] [Abstract][Full Text] [Related]
10. Identification of potential isoform-selective histone deacetylase inhibitors for cancer therapy: a combined approach of structure-based virtual screening, ADMET prediction and molecular dynamics simulation assay.
Uba AI; Yelekçi K
J Biomol Struct Dyn; 2018 Sep; 36(12):3231-3245. PubMed ID: 28938863
[TBL] [Abstract][Full Text] [Related]
11. Current trends in development of HDAC-based chemotherapeutics.
Cheshmazar N; Hamzeh-Mivehroud M; Nozad Charoudeh H; Hemmati S; Melesina J; Dastmalchi S
Life Sci; 2022 Nov; 308():120946. PubMed ID: 36096240
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic regulation of miR-200 as the potential strategy for the therapy against triple-negative breast cancer.
Mekala JR; Naushad SM; Ponnusamy L; Arivazhagan G; Sakthiprasad V; Pal-Bhadra M
Gene; 2018 Jan; 641():248-258. PubMed ID: 29038000
[TBL] [Abstract][Full Text] [Related]
13. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors.
Khan N; Jeffers M; Kumar S; Hackett C; Boldog F; Khramtsov N; Qian X; Mills E; Berghs SC; Carey N; Finn PW; Collins LS; Tumber A; Ritchie JW; Jensen PB; Lichenstein HS; Sehested M
Biochem J; 2008 Jan; 409(2):581-9. PubMed ID: 17868033
[TBL] [Abstract][Full Text] [Related]
14. Inhibitory selectivity among class I HDACs has a major impact on inflammatory gene expression in macrophages.
Cao F; Zwinderman MRH; van Merkerk R; Ettema PE; Quax WJ; Dekker FJ
Eur J Med Chem; 2019 Sep; 177():457-466. PubMed ID: 31181405
[TBL] [Abstract][Full Text] [Related]
15. Divergent JNK Phosphorylation of HDAC3 in Triple-Negative Breast Cancer Cells Determines HDAC Inhibitor Binding and Selectivity.
Hanigan TW; Aboukhatwa SM; Taha TY; Frasor J; Petukhov PA
Cell Chem Biol; 2017 Nov; 24(11):1356-1367.e8. PubMed ID: 28943357
[TBL] [Abstract][Full Text] [Related]
16. Structure optimization and preliminary bioactivity evaluation of N-hydroxybenzamide-based HDAC inhibitors with Y-shaped cap.
Yu C; He F; Qu Y; Zhang Q; Lv J; Zhang X; Xu A; Miao P; Wu J
Bioorg Med Chem; 2018 May; 26(8):1859-1868. PubMed ID: 29500131
[TBL] [Abstract][Full Text] [Related]
17. Identification of novel class I and class IIb histone deacetylase inhibitor for Alzheimer's disease therapeutics.
Gupta R; Ambasta RK; Kumar P
Life Sci; 2020 Sep; 256():117912. PubMed ID: 32504755
[TBL] [Abstract][Full Text] [Related]
18. Phenolic compounds as histone deacetylase inhibitors: binding propensity and interaction insights from molecular docking and dynamics simulations.
Uba AI; Zengin G
Amino Acids; 2023 May; 55(5):579-593. PubMed ID: 36781452
[TBL] [Abstract][Full Text] [Related]
19. Development and therapeutic impact of HDAC6-selective inhibitors.
Dallavalle S; Pisano C; Zunino F
Biochem Pharmacol; 2012 Sep; 84(6):756-65. PubMed ID: 22728920
[TBL] [Abstract][Full Text] [Related]
20. Hydroxamic acid derivatives as HDAC1, HDAC6 and HDAC8 inhibitors with antiproliferative activity in cancer cell lines.
Sixto-López Y; Gómez-Vidal JA; de Pedro N; Bello M; Rosales-Hernández MC; Correa-Basurto J
Sci Rep; 2020 Jun; 10(1):10462. PubMed ID: 32591593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
